Peptides for Inflammation: A Prescribing Clinic Map

Inflammation Is a Process, Not a Diagnosis

Most people who search for "peptides for inflammation" are describing a feeling rather than a lab value. A knee that stays puffy for weeks after a hard run. A gut that reacts to everything. A body that catches every cold in the office and takes twice as long to shake it. Those are three different situations, and the peptides that show up in the literature for each are not interchangeable.

Acute inflammation is the body doing its job: blood flow rises, immune cells arrive, damaged tissue gets cleared, repair begins, and it resolves in days. Chronic low-grade inflammation is the version that does not switch off. The same signaling molecules stay elevated for months and repair keeps stalling at the same step. A peptide that speeds resolution of the first kind is not automatically useful for the second. One more line worth drawing: "inflammation" is a physiological process, while inflammatory bowel disease, rheumatoid arthritis, or tendinopathy are diagnoses with their own standard of care. Nothing in the PeRx catalog treats, cures, or manages any of those. The research describes how specific peptides act on inflammatory signaling in cells and animals, and in a few cases in people. Every claim below carries that tier.

The Three Peptides We Supply

BPC-157

BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice, first described by the Sikiric group in Zagreb in the early 1990s. Its studied mechanisms are about repair rather than suppression. In animal and cell models it upregulates VEGFR2 signaling, promotes new blood vessel formation, and drives fibroblast migration into damaged tendon. That is a different logic from an NSAID, which blocks a step in the inflammatory cascade; BPC-157 in the models appears to help the cascade finish. The long version is in our complete BPC-157 guide Read nextBPC-157: Complete Guide to Body Protection CompoundA peptide discovered in a Croatian lab in the early '90s is now one of the most studied healing compounds in regenerative medicine. Here's what the science actually says, where it came from, and what you should know before starting.Read article .

Chang CH et al., "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration," Journal of Applied Physiology, 2011. Rat tendon explant and cell-culture model. View study

At PeRx, BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide comes two ways. The injectable is a 3 mg/mL, 5 mL vial for $229 per prescription, dosed at 20 units (0.2 mL) under the skin once daily, as close to the injury site as practical. BPC capsules are 500 mcg oral doses, 30 for $200, taken every morning on an empty stomach. Both run 6 weeks on, then 6 weeks off.

KPV, Inside the KLOW Blend

KPV is lysine-proline-valine, the three-amino-acid tail of the hormone alpha-MSH. Researchers isolated it because it kept the anti-inflammatory activity of the parent hormone without the pigment effects. In cell and mouse work, KPV enters cells through the PepT1 transporter and dampens NF-kB signaling, the switch that turns on many inflammatory genes. Two 2008 papers, one in Gastroenterology and one in Inflammatory Bowel Diseases, showed reduced inflammatory markers in mouse colitis models. That is the tier: mouse. Our full KPV explainer Read nextWhat Is KPV? The Peptide Inside KLOWKPV is three amino acids long, which makes it one of the smallest molecules anyone calls a peptide. It came out of hormone research in the late 1980s, it has a real literature behind it, and almost none of that literature involves humans. Here is what is actually known, why PeRx only supplies it inside a four-peptide blend, and what the July 2026 FDA panel vote did and did not do.Read article walks through every study.

Dalmasso G et al., "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation," Gastroenterology, 2008. Kannengiesser K et al., "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease," Inflammatory Bowel Diseases, 2008. Both mouse models. View study

PeRx does not sell KPV on its own. It is supplied only inside KLOW, a four-peptide subcutaneous blend of BPC-157, GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide , KPV, and TB-500 at 3 mg, 10 mg, 3 mg, and 3 mg per mL. The blend costs $349 per prescription and is dosed at 20 units Monday through Friday near the injury site, 6 weeks on and 6 weeks off. The reasoning is simple: KPV has no meaningful human data as a standalone, so we pair it with peptides that address the repair side of the same problem rather than prescribing it alone.

Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from the thymus. It is the one peptide in this guide that works on the immune system itself rather than on a damaged tissue. It promotes T-cell maturation and dendritic-cell activity, which is why the clinical trials that exist are in people whose immune response is blunted: chronic hepatitis B patients on antivirals, and severe COVID-19 patients with depleted lymphocytes. Those are medical populations, not wellness ones, but they are randomized human data, a different tier from the other two. Details in our Thymosin Alpha-1 guide Read nextThymosin Alpha-1 2026: The Vanishing Immune HormoneYour immune system has a master gland. It trained every T-cell you've ever had. And it started disappearing the day you hit puberty. Shrinking, replaced by fat, producing less of the hormone that keeps your defenses sharp. In 1974, a dying five-year-old became the first human to receive that hormone. Her life was saved. Today, the synthetic version is approved in 35+ countries, has been given to patients ages 13 months to 101 years, and has the strongest safety profile of any peptide in clinical use. Here's everything you need to know about Thymosin Alpha-1.Read article .

Liu Y et al., "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells," Clinical Infectious Diseases, 2020. Zhang YY et al., lamivudine with and without thymosin alpha-1 in chronic hepatitis B, meta-analysis, Virology Journal, 2009. View study

Thymosin Alpha-1 Explore PeRxThymosin Alpha-1Immune System OptimizerView peptide at PeRx is a 5 mg/mL, 5 mL vial for $229, dosed at 20 units (1 mg) subcutaneously once daily Monday through Friday. Unlike BPC-157 and KLOW, it does not require a cycling break. Side effects in the trial literature are uncommon, mostly injection-site redness.

What We Do Not Supply, and Why

LL-37. An antimicrobial peptide with immunomodulatory activity in cell studies. It was on the FDA list of peptides nominated for 503A review, but the agency deferred it, along with GHK-Cu, Dihexa, Melanotan II, and PEG-MGF, to a later advisory meeting scheduled before the end of February 2027. We do not carry substances still in that queue as standalone products.

Standalone TB-500. TB-500 (a thymosin beta-4 fragment) has an animal literature on wound healing and cell migration, and the advisory committee recommended it on July 23, 2026. We ship it only inside a combination: KLOW, the BPC-157/TB-500 blend Explore PeRxBPC/TB-500The Ultimate Recovery ComboView peptide , or the oral BPC/TB-500 capsules. Our reasoning is in why we pair BPC-157 and TB-500 Read nextWhy We Pair BPC-157 With TB-500BPC-157 and TB-500 are both repair peptides, but they cover different ground. BPC-157 works fast and focal, strongest at a specific injury and in the gut. TB-500 works broad and systemic, moving repair cells across the whole body. The pairing is not automatic. Here is how a provider decides whether you need both, or whether BPC-157 on its own does the job.Read article . Everything else labeled "anti-inflammatory" on research-chemical sites. If a 503A pharmacy cannot compound it from a substance with defensible regulatory footing, a prescriber cannot write for it, and we do not list it.

Match the Peptide to the Inflammation You Are Describing

After an injury: tendon, ligament, joint

A joint or tendon still swollen and sore weeks after the original strain is the most common inflammation complaint on our intake. The literature that applies is the BPC-157 tendon and ligament work in animals, plus the small human reports on knee injection. This is where injectable BPC-157 fits, dosed near the site. If the injury involves broader soft-tissue damage or skin, KLOW adds TB-500 for cell migration and GHK-Cu for collagen signaling. Patients in this group commonly report stiffness easing in the first two to three weeks; many notice nothing until week four or beyond.

In the gut

Bloating, food reactivity, and a gut that "runs hot" are a different problem, and here the route matters more than the peptide. BPC-157 was discovered in gastric juice, and oral capsules put it in direct contact with the intestinal lining, the tissue you are trying to reach. Injected BPC-157 reaches the gut through circulation at far lower local concentration. So BPC capsules are usually the starting point for a gut-focused complaint, with KLOW as the second option when the picture is broader. The KPV mouse data lives here too, unreproduced in humans. Trade-offs are in BPC-157 oral vs injectable bioavailability Read nextBPC-157 Oral vs Injectable: Which Route WinsBPC-157 is the rare peptide with a real oral story, but that does not mean capsule and injection are interchangeable. A physician-reviewed breakdown of gut-local vs systemic delivery, what survives digestion, and how providers choose the route.Read article and how we approach gut health peptides Read nextHow We Approach Gut-Health PeptidesMost conventional GI care suppresses symptoms: acid blockers for reflux, anti-diarrheals for IBS. Gut peptides aim at the layer underneath, the barrier itself. BPC-157 does the structural repair, glutathione defends against oxidative damage, and Thymosin Alpha-1 modulates the immune tissue that surrounds the gut. Here is how a provider decides which layer you actually need, and what peptides will not fix.Read article .

Immune recovery

The third pattern is not a single sore spot. It is the person who gets sick often, recovers slowly, and feels inflamed all over without a clear injury. Tissue-repair peptides are the wrong tool. Thymosin Alpha-1 is the candidate because its studied mechanism is immune modulation rather than local repair. The provider will want to know about any autoimmune history, because a peptide that increases T-cell activity is not something to prescribe blindly to someone whose immune system is already overactive.

Side-by-Side Comparison

Prices are per prescription as of August 27, 2026 and include the vial or capsules, syringes and swabs where applicable, and overnight refrigerated shipping. Prices are visible on product pages after you create an account.

Evidence Tiers, Honestly

A fair reading ranks these three in an order that surprises people. Thymosin Alpha-1 sits at the top on human evidence, with randomized trials and meta-analyses. The catch is that those trials enrolled hepatitis B and severe COVID-19 patients, so extrapolating to a healthy adult who feels run down is a real leap. The mechanism carries over; the trial outcomes do not. BPC-157 has the broadest literature, well over 100 papers across three decades, but the great majority are rat and mouse studies from a small number of labs. A 2019 review in Cell and Tissue Research summarized the soft-tissue data and noted the absence of controlled human trials. The human reports since are small: a 2021 knee-injection case series reported 87.5 percent of patients with lasting relief, with no control group.

Gwyer D, Wragg NM, Wilson SL, "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing," Cell and Tissue Research, 2019. Lee E, Padgett B, "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain," Alternative Therapies in Health and Medicine, 2021. View study

KPV is the thinnest. Its anti-inflammatory activity is well characterized in cell culture and mouse colitis models, and a 2017 paper studied its delivery across human skin tissue, but no completed human efficacy trial exists as of this writing. That is the honest reason PeRx will not sell it alone. If a site calls KPV "the strongest anti-inflammatory peptide," ask what species that claim comes from. The best peptide for inflammation is the one whose evidence tier matches the problem you actually have.

The July 2026 FDA Panel Vote

On July 23 and 24, 2026 the FDA Pharmacy Compounding Advisory Committee met to review seven peptides for the 503A bulks list, the list of substances licensed compounding pharmacies may prepare. FDA staff briefing documents recommended against adding all seven; the committee disagreed on six. Two of the three peptides in this guide were on the agenda. BPC-157 was reviewed in the context of a nominated ulcerative colitis use, and the committee voted 8 to 6, with one abstention, to recommend it. KPV was reviewed for wound healing and was also recommended 8 to 6 with one abstention. TB-500, a component of KLOW, was recommended the same day. Thymosin Alpha-1 was not on this agenda. The complete tally is in our panel results recap Read nextFDA Panel Backs 6 of 7 Peptides, Rejects DSIPThe FDA's Pharmacy Compounding Advisory Committee finished its two-day meeting on July 24, 2026. By the end, it had voted to recommend six of the seven peptides on the agenda for the 503A compounding list, including BPC-157, TB-500, MOTS-C, Semax, and Epitalon, and against just one, Emideltide (DSIP). Every vote went against the FDA's own scientists. Here is the full tally, what it changes, and what it does not.Read article .

What the Provider Reviews

The PeRx intake is a screening form, not a consultation. A licensed provider reads it and either prescribes a standard protocol or declines. For an inflammation-related request the review turns on four things. The location and timeline of the complaint, for the sorting reasons above. Current medications, especially NSAIDs: the BPC-157 and KLOW protocols ask you to avoid ibuprofen, naproxen, and aspirin during the course, because the peptides support a repair process that NSAIDs blunt. Immune history, since an autoimmune diagnosis, a transplant, or immunosuppressant use changes the picture for Thymosin Alpha-1 and for the KPV in KLOW. And cancer history, because BPC-157 and TB-500 promote blood vessel growth in models, the wrong lever to pull near a tumor.

Most inflammation-related requests need no lab work. The provider can ask for labs if something warrants it, and can decline. If the intake reads like a diagnosed condition with its own standard treatment, the provider will point you back to the physician managing it rather than prescribe around it.

What a Typical Course Looks Like

Common Questions